Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antabio is advancing several discovery-stage programs focused on identifying small molecule inhibitors against novel, undisclosed bacterial targets to combat antimicrobial resistance (AMR). These initiatives include a partnership with the Global Antibiotic Research and Development Partnership (GARDP) to develop new chemical series for high-priority resistant pathogens. By targeting biological pathways distinct from those addressed by current antibiotics, these programs aim to provide new therapeutic options for infections where existing treatments are failing. As these candidates are in the discovery phase, specific chemical structures and precise mechanisms of action remain proprietary.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antabio novel target small molecule program.